Kyttaro plans to develop a peptide technology platform to create novel biologic therapeutics addressing various causes of inflammation, a major mechanism underlying cardiovascular disease.
The technology used to identify this gene has been exclusively licensed to Nucleome, highlighting the competitive advantage of Nucleome\u2019s platform in the discovery of genetic targets for innovative precision medicine development.
Exogene has been selected as one of ten innovative startup companies, working at the interface of biomedical and data science, to receive personalised mentoring and coaching as part of the KQ Labs accelerator programme.
Kyttaro is developing innovative therapeutics to treat hypertriglyceridemia, atherosclerotic cardiovascular disease and inflammatory and neurogastroenterology conditions.
Recipients of the OBN Awards are considered to have made an outstanding and valuable contribution to their field, which is why Ochre Bio is thrilled to have made the cut at this early stage of its life.
The inaugural Libra programme has been set up to support tech leadership teams with at least one Black or multiracial founder and to promote diversity and equal opportunities in the sector.
The BioEscalator concept was born out of a shared need by academic researchers and their bioscience company collaborators for start-up incubator space close to academic labs. The vision was to develop a leading international centre for innovative bioscience with the potential to make a significant impact on healthcare. The incubator provides spin-outs and start-ups with laboratory and business support, enabling them to grow into leading bioscience ventures.
Despite the disruption caused by the pandemic, BioEscalator companies attracted a record high of \u00a31.2B investment. This is part of a trend that saw investors attracted to the resilience displayed by the life science industry to the pandemic relative to other sectors.
Proceeds to support expansion and advancement of PepGen\u2019s pipeline of Enhanced Delivery Oligonucleotide (EDO) therapies for neuromuscular and neurologic diseases.
After a highly successful start, Theolytics is ready for the next step in its journey and is moving to The Oxford Science Park. The company will be the first tenant moving into the newly refurbished Sherard Building.
Oxford Silk Phage Technologies combines the long-term expertise of clinicians, entrepreneurs and scientists with a shared passion for developing superior, natural antibacterial biomaterials to help people live more active and longer lives.
MediMabBio has started global clinical trials of its flagship pipeline. After securing R&D funding through a Series A round earlier this year, it will collaborate with a UK clinical trial institution to conduct joint research to develop a treatment for liver cancer.
The funding will be used to advance the development of Ochre Bio\u2019s RNA therapies and expand its deep phenotyping platform to identify and validate new liver targets.
OXvax Ltd. is a spin-out company from the University of Oxford focused on developing an advanced next-generation dendritic cell vaccine platform for treating solid tumour cancers.
Alchemab Therapeutics, a former resident company at Oxford's BioEscalator, has won Best Start-up Biotech Company at the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London.
PepGen wins the BioEscalator Pitch Battle 2021 with an excellent pitch on how the company is harnessing the power of its Enhanced Delivery Peptide technology to solve the drug-delivery challenge and realize the clinical potential of oligonucleotide therapies to transform the lives of people living with neuromuscular diseases.
![\"Kyttaro](\"https://www.bioescalator.ox.ac.uk/news/kyttaro-announces-an-exclusive-worldwide-licensing-agreement-with-oxford-university-innovation/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n